Publication Date:
2017-07-27
Description:
Commentary on: Abraham NS, Noseworthy PA, Yao X, et al . Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology 2017;152:1014–1022.e1. Context Oral anticoagulation (OAC) reduces the risk of stroke and mortality in atrial fibrillation (AF). The known limitations of vitamin K antagonists (VKAs) have led to the development of non-vitamin K oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban and edoxaban. These anticoagulants are at least as effective as VKAs for prevention of stroke in patients with AF and safer in terms of serious bleeding events. 1–3 Given that high rates of gastrointestinal (GI) bleeding have been observed in NOACs, 1 Abraham et al report a ‘real world’ study of the GI safety profile comparing the various NOACs head-to-head. Methods Abraham et al enrolled both inpatients and outpatients with non-valvular AF who started dabigatran, apixaban or rivaroxaban during 1 October 2010 to 28 February...
Print ISSN:
1356-5524
Electronic ISSN:
1473-6810
Topics:
Medicine
